BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for 4D Molecular Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 4:20 pm Sale |
2024-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
BIOTECHNOLOGY VALUE FUND L P | 4,834,297 9.990% |
-2,548,345 (-34.52%) |
Filing |
| 2024-11-13 4:08 pm Purchase |
2024-09-30 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
BIOTECHNOLOGY VALUE FUND L P | 7,382,642 14.200% |
3,375,229 (+84.22%) |
Filing |
| 2024-02-14 09:56 am Unchanged |
2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
BIOTECHNOLOGY VALUE FUND L P | 4,007,413 9.400% |
0 (Unchanged) |
Filing |
| 2022-06-21 4:53 pm Purchase |
2022-06-16 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
BIOTECHNOLOGY VALUE FUND L P | 4,007,413 12.400% |
2,001,551 (+99.79%) |
Filing |
| 2021-07-06 5:01 pm Purchase |
2021-06-25 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
BIOTECHNOLOGY VALUE FUND L P | 2,005,862 7.500% |
2,005,862 (New Position) |
Filing |